161 related articles for article (PubMed ID: 9372543)
1. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
Durand RE; Olive PL
Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
[TBL] [Abstract][Full Text] [Related]
2. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
Olive PL; Vikse CM; Banath JP
Cancer Res; 1996 Oct; 56(19):4460-3. PubMed ID: 8813141
[TBL] [Abstract][Full Text] [Related]
3. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
[TBL] [Abstract][Full Text] [Related]
4. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
5. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Siim BG; Menke DR; Dorie MJ; Brown JM
Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Masunaga S; Nagasawa H; Uto Y; Hori H; Suzuki M; Nagata K; Kinashi Y; Ono K
Int J Hyperthermia; 2005 Jun; 21(4):305-18. PubMed ID: 16019857
[TBL] [Abstract][Full Text] [Related]
9. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
11. Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.
Govaert KM; Nijkamp MW; Emmink BL; Steller EJ; Minchinton AI; Kranenburg O; Borel Rinkes IH
Br J Surg; 2012 Apr; 99(4):567-75. PubMed ID: 22331808
[TBL] [Abstract][Full Text] [Related]
12. DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Birincioglu M; Jaruga P; Chowdhury G; Rodriguez H; Dizdaroglu M; Gates KS
J Am Chem Soc; 2003 Sep; 125(38):11607-15. PubMed ID: 13129365
[TBL] [Abstract][Full Text] [Related]
13. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
Olive PL
Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
[TBL] [Abstract][Full Text] [Related]
14. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
15. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
17. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
18. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.
Bains LJ; Baker JH; Kyle AH; Minchinton AI; Reinsberg SA
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):957-65. PubMed ID: 19480975
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie MJ; Brown JM
Cancer Res; 1993 Oct; 53(19):4633-6. PubMed ID: 8402639
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
